Moderna Stock

Moderna P/B

The P/B (Price-to-Book Ratio) of Moderna (MRNA) as of Aug 4, 2026 is 1.91. In the previous year, P/B (Price-to-Book Ratio) was 1.51 — a change of 26.02% (higher).

P/B

1.91

YoY

26.02%

Last updated:

P/B (Price-to-Book Ratio) of Moderna is 2026 1.91 . P/B (Price-to-Book Ratio) of Moderna was 2025 1.51 . It decreases by 26.02% higher compared to the previous year.
Access this data via the Eulerpool API

Moderna Stock analysis

What does Moderna do? Moderna Inc is a biotechnology company from the USA that specializes in the development of therapies and vaccines based on mRNA technology. The company was founded in 2010 by a group of researchers led by Noubar Afeyan and is headquartered in Cambridge, Massachusetts. Moderna is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Moderna stock

P/B (Price-to-Book Ratio) of Moderna is 1.91 in 2026.

P/B (Price-to-Book Ratio) of Moderna changed from 1.51 to 1.91, representing a 26.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Moderna since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Moderna with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Moderna

All Key Metrics — Moderna